Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer
Breast cancer continues to have a high incidence rate among female malignancies. Despite significant advancements in treatment modalities, the heterogeneous nature of breast cancer and its resistance to various therapeutic approaches pose considerable challenges. Antibody-drug conjugates (ADCs) effe...
Saved in:
Main Authors: | Yan Liang (Author), Purong Zhang (Author), Feng Li (Author), Houyun Lai (Author), Tingting Qi (Author), Yixin Wang (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
New antibody-drug conjugates (ADCs) in breast cancer-an overview of ADCs recently approved and in later stages of development
by: Kira-Lee Koster, et al.
Published: (2022) -
Emerging non-antibody‒drug conjugates (non-ADCs) therapeutics of toxins for cancer treatment
by: Xiaolan Xu, et al.
Published: (2024) -
Antibody-drug conjugates (ADCs) may be a big breakthrough in gynecologic cancer treatment (I)
by: Peng-Hui Wang, et al.
Published: (2024) -
Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)-A Necessity for Future ADC Research and Development
by: Manar Hammood, et al.
Published: (2021) -
Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database
by: PingPing Long, et al.
Published: (2024)